Member Info for neo2725

+200% export sales. Very promising

http://www.alignresearch.co.uk/yourgene-health/yourgene-health-covid-assay-not-compromised-by-new-viral-strain/

New target 39p

Correct. Angle will not be the first to market a product like this, the existing technology traps and kills the CTCs and the sensitive is not as high as Angle.. Angle tech allows you to isolate alive cells, grow up and test them against multiple cancer drugs to determine which one will kill the tumour cells, therefore reducing treatment delay and minimise drug costs. +37 peer reviewed papers confirming the science which some papers evening spiking a blood sample with a single cancer cell, passing the blood through the technology and being able to both detect and then remove this spiked cell. Incredible when you think about it.

7min video on where dest is released 2 days ago https://www.proactiveinvestors.co.uk/companies/news/937868/destiny-pharma-mark--exciting-time-completing-studies-and-delivering-data--937868.html

Another +10% day in a row, quality always shines through in the end

Nice few buys in, some reasonable purchases this week and if you look at the monthly chart we are in a uptrend. January is going to be a troublesome month for U.K. schools, newsnight yesterday had a nice piece on U.K. schools and attendance (about half way through the programme). Basically schools are running at 80% capacity due to teacher or student self isolating
Previous

Some calculations for us all, I have been working out the free float before and after the recent placing, before is easy to work out via the destiny website under the capital structure tab or just type destiny pharma major stakeholders into google and it’s the first link. It was 66.6% of all shares held by major investors so a free float of shares for us PIs of 33.4% of remaining shares.

Now after the recent placing we need to dilute these down by the additional 15.9million new shares which hit the market on Monday giving 59,816,921 shares currently in issue, about a 26% dilution by my maths, factor in the two RNS from Sir Nigel Rudd and Unicorn assets management who have taken a 3% and 5% stake this gives a current free float of about 43% shares in private hands.

This is 25,700,000 shares give or take, I imagine as we approach results in q1 2021 this pool of shares will reduce and we may see increase in share price. I cannot see people who have taken part in the placing selling for sub 65p. With broker targets of £2.60 and £3 on a successful trial this share has much upside and little down IMO but do your own research.

Been reading up NTCD-M3 and the JAMA paper available via the dest website. This treatment is very similar to 4D pharma approach and looks promising, especially as dest now have the global rights to this treatment. Remember folks the key thing that kills many clinical trials is toxicity and these treatments are shown have very low toxicity. It’s better to give a treatment with a small positive effect with zero side effects than a treatment with major benefits and dangerous side effects.

Peer reviewed paper of the phase 2 results of this treatment which is haze 3 ready. destiny have the global rights to market this treatment through a recent placing at 65p

https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2015.3725

Destiny pharma #dest new phase 3 ready drug targeting gut bacteria is very similar 4D pharma #dddd approach to treating patients with a less harmful strain of bug, in this case c.difficile. Phase 2 trial of XF-73 results for MRSA bugs in hospital due q1 2021, one to watch ??
https://www.destinypharma.com/pipeline/clostridioides-difficile-infections/

It’s a pin prick of blood, possibly diluted further by the addition of a few drops of buffer solution like the Innova tests. This solution is then diluted further by its absorption on the pad as it travels up the LFT. After a few hours it will be dried and little little which could be further reduced by sealing in a bag before disposal in normal household waste streams. Female period products contain more blood and carry similar blood risks but with higher blood volumes.

I’m recently invested too. I have been reading the published paper on the phase 1 trial and other related papers. This is looking a very attractive investment and on good results I easily see this hitting the £2 - £2.50 mark but more likely we will see a steady rise daily as we approach end of q1 2021.

Very healthy buying last two days, hold tight all

They have to let people see family and friends as Christmas, extending the lockdown will leave to mass rule breaking and the failure of any further lockdowns. Furthermore Boris wants to save Christmas and I think he will stick to the 2nd December deadline

Government providing tuition to kids who missed out on classes, very good chance WEY will take a large portion of these funds, they are the U.K. number 1 provider https://www.bbc.co.uk/news/education-54753088

Primer on Wey if interested https://leoinvestoruk.home.blog/2020/10/20/wey-education-results-preview/

https://www.theguardian.com/education/2020/sep/30/rise-in-home-schooling-is-partly-down-to-misinformation-says-ofsted-chief

We could be following in 3-4 weeks with a full national lockdown or tier 4 as it will be called. If there ever was a time for a rapid antigen test it’s now.

It’s the Mologic antigen test currently under evaluation at Heathrow, why did Colin erm and ah and not clearly state it’s been tested at Liverpool school of tropical medicine, Nottingham university and Heathrow airport the largest airport in the Uk. I mean it’s clear to see if Mologic test is chosen by Heathrow as the test of choice to allow mass flights to happen other airports will follow and Mologic lateral flow antigen test will become the global gold standard test to save the airline and travel industries combined.

So thoughts on the unnamed investor Kieran mentioned? Could it be some kind of charity organisation / bigger company building up a stake in ODX?